Prokarium’s Foundational technology leverages inherent anti-tumor mechanisms of a proprietary strain of bacteria (ZH9) as a microbial immunotherapy platform

  • Naturally tumor targeting and oncolytic
  • Overcomes the suppressive tumor microenvironment
  • Targets multiple pathways to elicit strong anti-tumor immunity
  • Extensive opportunities to deliver diverse cargo
Proprietary ZH9 Chassis Strain

BLADDER CANCER​

PARADIGM, [RE]DESIGNED

Transforming the treatment paradigm in the
costliest cancer to become the new standart-of-care in a market that has seen little innovation in >30 years

IMMUNOTHERAPY (IO) PRIME

FITNESS, [RE]STORED

Restoring anti-tumor responses with an oral immune training agent to boost efficacy of immunotherapies for the 80% of patients unable to benefit today

LIVING CURES PLATFORM

EVOLUTION, [RE]PROGRAMMED

Reprogramming Salmonella with bespoke synthetic circuits to deliver diverse therapeutic cargo for difficult-to-treat cancers

BLADDER CANCER

PARADIGM, [RE]DESIGNED

Bladder cancer is one of the costliest cancers to treat with 550.000 new cases annually worldwide, representing 5% of all new cases in the US. The clinical staging is determined by the depth of tumor invasion into the bladder wall and more than 70% of patients are diagnosed at an early stage, known as non-muscle invasive bladder cancer (NMIBC). Despite early diagnosis, and treatment with standard-of-care Bacillus Calmette-Guerin (BCG), up to 80% of patients recur increasing the risk of progression. Because of bladder cancer’s high incidence, frequent recurrences, and low number of treatment options, a huge unmet medical need remains.

ABOUT US

PIPELINE

Indication

Discovery

Preclinical

IND-enabling

Phase 1

ZH9 - Bladder cancer
Non-muscle invasive

Discovery

Preclinical

IND-enabling

Phase 1

Phase 1 initiated in US

Indication

ZH9 - Bladder cancer
Muscle invasive

Discovery

Preclinical

IND-enabling

Phase 1

Combination with checkpoint inhibitors

Indication

IO Prime

Discovery

Preclinical

IND-enabling

Phase 1

First-in-class oral immune fitness agent ready to enter the clinic

Indication

Living Cures Platform

Discovery

Preclinical

IND-enabling

Phase 1

Discovery cargo-delivery IO platform

London, UK – February 7, 2024 –  Prokarium, a clinical-stage biopharmaceutical company bioengineering Living Cures through cutting-edge synthetic...
London, UK – November 2, 2023 – Prokarium, a biopharmaceutical company at the forefront of applying synthetic biology to create...
London, UK – November 2, 2023 – Prokarium, a biopharmaceutical company at the forefront of applying synthetic biology to create...
London, UK February 9, 2023 – Prokarium, a biopharmaceutical company leading the oncology field of microbial immunotherapy, has...
London, UK February 9, 2023 – Prokarium, a biopharmaceutical company leading the oncology field of microbial immunotherapy, has...
LONDON, UK and BOSTON, MA — January 9, 2023 — Prokarium, a biopharmaceuticalcompany pioneering the oncology field of...
LONDON, UK and BOSTON, MA — January 9, 2023 — Prokarium, a biopharmaceuticalcompany pioneering the oncology field of...
LONDON, UK – October 19, 2022 – Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy,...
LONDON, UK – October 19, 2022 – Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy,...
LONDON, United Kingdom, October 5, 2022 – Prokarium Ltd (‘Prokarium’ or the ‘Company’), a biopharmaceutical company pioneering the...
LONDON, United Kingdom, October 5, 2022 – Prokarium Ltd (‘Prokarium’ or the ‘Company’), a biopharmaceutical company pioneering the...
LONDON, UK – March 2, 2022 – Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy,...
LONDON, UK – March 2, 2022 – Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy,...
LONDON, UK – January 26, 2022 – Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy,...
LONDON, UK – January 26, 2022 – Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy,...
LONDON, UK – November 11, 2021– Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy, today...
LONDON, UK – November 11, 2021– Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy, today...
LONDON, UK – November 2, 2021 – Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy,...
LONDON, UK – November 2, 2021 – Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy,...
London / Amsterdam – October 12, 2021 – Prokarium, a biopharmaceutical company pioneering the oncology field of microbial...
London / Amsterdam – October 12, 2021 – Prokarium, a biopharmaceutical company pioneering the oncology field of microbial...
LONDON, UK – October 5, 2021 – Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy,...
LONDON, UK – October 5, 2021 – Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy,...
LONDON, UK – July 27, 2021 – Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy,...
LONDON, UK – July 27, 2021 – Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy,...
Entervax is a novel bivalent oral vaccine against enteric fever, currently in a phase 1 trial with the...
Entervax is a novel bivalent oral vaccine against enteric fever, currently in a phase 1 trial with the...
– Industry veteran, Hyam Levitsky, MD, appointed to Prokarium’s Board of Directors – Financing will support the clinical...
– Industry veteran, Hyam Levitsky, MD, appointed to Prokarium’s Board of Directors – Financing will support the clinical...
Prokarium welcomes Hyam Levitsky and David Holden as new advisors.
Prokarium welcomes Hyam Levitsky and David Holden as new advisors.
Kristen Albright, Prokarium’s CEO, Dara Henry, Prokarium’s COO and Livija Deban, Prokarium’s CSO, will be attending J.P. Morgan...
Kristen Albright, Prokarium’s CEO, and Dara Henry, Prokarium’s COO, will be attending Jeffries 2023 London Healthcare Conference, 14...
Kristen Albright, Prokarium’s CEO, will be presenting at the LSX Investival Showcase event on 13 November in London.
Dara Henry, Prokarium’s COO, will be attending Bio-Europe 2023 in Munich, from 6-8th November 2023.

Design the future with us

Icons